Can-Fite BioPharma (CANF) and Its Peers Head-To-Head Contrast

Can-Fite BioPharma (NYSE:CANF) is one of 896 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare Can-Fite BioPharma to similar companies based on the strength of its valuation, profitability, institutional ownership, dividends, analyst recommendations, earnings and risk.

Profitability

This table compares Can-Fite BioPharma and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Can-Fite BioPharma	N/A	N/A	N/A
Can-Fite BioPharma Competitors	-2,380.39%	-218.78%	-15.59%

Insider and Institutional Ownership

21.0% of Can-Fite BioPharma shares are owned by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 0.8% of Can-Fite BioPharma shares are owned by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Can-Fite BioPharma and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Can-Fite BioPharma	0	1	2	0	2.67
Can-Fite BioPharma Competitors	7798	13891	25784	1038	2.41

Can-Fite BioPharma presently has a consensus target price of $44.00, suggesting a potential upside of 2,550.60%. As a group, “Pharmaceuticals” companies have a potential upside of 24.75%. Given Can-Fite BioPharma’s stronger consensus rating and higher probable upside, research analysts clearly believe Can-Fite BioPharma is more favorable than its peers.

Earnings and Valuation

This table compares Can-Fite BioPharma and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Can-Fite BioPharma	$405,000.00	-$7.63 million	-0.11
Can-Fite BioPharma Competitors	$5.34 billion	$3.21 billion	553.85

Can-Fite BioPharma’s peers have higher revenue and earnings than Can-Fite BioPharma. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

Can-Fite BioPharma has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, Can-Fite BioPharma’s peers have a beta of -3.71, suggesting that their average stock price is 471% less volatile than the S&P 500.

Summary

Can-Fite BioPharma beats its peers on 7 of the 13 factors compared.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.